JP2002529097A5 - - Google Patents

Download PDF

Info

Publication number
JP2002529097A5
JP2002529097A5 JP2000581225A JP2000581225A JP2002529097A5 JP 2002529097 A5 JP2002529097 A5 JP 2002529097A5 JP 2000581225 A JP2000581225 A JP 2000581225A JP 2000581225 A JP2000581225 A JP 2000581225A JP 2002529097 A5 JP2002529097 A5 JP 2002529097A5
Authority
JP
Japan
Prior art keywords
tumor
compound
product
medicament
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000581225A
Other languages
English (en)
Japanese (ja)
Other versions
JP4733833B2 (ja
JP2002529097A (ja
Filing date
Publication date
Priority claimed from GBGB9824437.9A external-priority patent/GB9824437D0/en
Application filed filed Critical
Publication of JP2002529097A publication Critical patent/JP2002529097A/ja
Publication of JP2002529097A5 publication Critical patent/JP2002529097A5/ja
Application granted granted Critical
Publication of JP4733833B2 publication Critical patent/JP4733833B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000581225A 1998-11-06 1999-11-05 アデノウィルスを介する遺伝子治療 Expired - Fee Related JP4733833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
GB9824437.9 1998-11-06
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (3)

Publication Number Publication Date
JP2002529097A JP2002529097A (ja) 2002-09-10
JP2002529097A5 true JP2002529097A5 (cg-RX-API-DMAC7.html) 2006-12-21
JP4733833B2 JP4733833B2 (ja) 2011-07-27

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000581225A Expired - Fee Related JP4733833B2 (ja) 1998-11-06 1999-11-05 アデノウィルスを介する遺伝子治療

Country Status (18)

Country Link
US (1) US6579855B1 (cg-RX-API-DMAC7.html)
EP (1) EP1135513B2 (cg-RX-API-DMAC7.html)
JP (1) JP4733833B2 (cg-RX-API-DMAC7.html)
KR (1) KR20020013473A (cg-RX-API-DMAC7.html)
CN (1) CN1184321C (cg-RX-API-DMAC7.html)
AT (1) ATE341639T1 (cg-RX-API-DMAC7.html)
AU (1) AU749451B2 (cg-RX-API-DMAC7.html)
CA (1) CA2348624C (cg-RX-API-DMAC7.html)
CY (1) CY1106198T1 (cg-RX-API-DMAC7.html)
DE (1) DE69933468T3 (cg-RX-API-DMAC7.html)
DK (1) DK1135513T4 (cg-RX-API-DMAC7.html)
ES (1) ES2273521T5 (cg-RX-API-DMAC7.html)
GB (1) GB9824437D0 (cg-RX-API-DMAC7.html)
HU (1) HUP0104046A3 (cg-RX-API-DMAC7.html)
NO (1) NO330776B1 (cg-RX-API-DMAC7.html)
PL (1) PL193076B1 (cg-RX-API-DMAC7.html)
PT (1) PT1135513E (cg-RX-API-DMAC7.html)
WO (1) WO2000028059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) * 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
US12559576B2 (en) 2021-11-11 2026-02-24 Regeneron Pharmaceuticals, Inc. CD20-PD1 binding molecules and methods of use thereof
AU2024207005A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
KR20260113057A (ko) 2023-11-14 2026-07-21 리제너론 파아마슈티컬스, 인크. 조작된 중쇄 가변 도메인 및 이의 용도
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Similar Documents

Publication Publication Date Title
CA2348624A1 (en) Adenovirus-mediated gene therapy
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
DE69533128D1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
US8771663B2 (en) Formulation having mobilising activity
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
WO2000053730A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
WO2002045431A3 (en) Genetically engineered herpes virus for the treatment of cardiovascular disease
JP2002532432A5 (cg-RX-API-DMAC7.html)
BR9807319A (pt) Microgrânulos com liberação controlada, para administração oral, contendo cisplatina, processo de preparação dos mesmos, preparação farmacêutica, e, utilização dos microgrânulos.
WO1998000541A3 (en) Methods for administration of recombinant gene delivery vehicles for treatment of human disease
RU97104483A (ru) Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента
JP2002530353A5 (cg-RX-API-DMAC7.html)
Soria et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose
JP2003534282A5 (cg-RX-API-DMAC7.html)
WO2003084979A3 (fr) Peptides et leur application en therapeutique
US20170348345A1 (en) Combination Therapy For Cancer
WO2006127938A1 (en) Methods and compositions using 4[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperridin-3yl) isoindole-1,3-dione for the treatment of prevention of cutaneous lupus
Suntsova et al. Use of romiplostim for newly diagnosed immune thrombocytopenia in children
AR004196A1 (es) Un metodo a alta velocidad para preparar granulos esfericos que comprende un medicamento para uso farmaceutico, granulos obtenibles mediante este metodoy una bolsita que contiene dichos granulos
ZA202304877B (en) Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
JP2005502690A5 (cg-RX-API-DMAC7.html)
US7671038B1 (en) Method of therapeautic treatments including human immunodeficiency virus (HIV) disease and other conditions in a human host by administering adenine nucleotides
van der Veen et al. Stealth® liposomal tumor necrosis factor-α in solid tumor treatment
JP2002529515A5 (cg-RX-API-DMAC7.html)
JPH0551565B2 (cg-RX-API-DMAC7.html)